Skip to content

MDMA: all studies

Page 86 of 346: studies 851 to 860 of 3,454, newest first. Back to the MDMA overview

Research

Neurochemical substrates of the rewarding effects of MDMA: implications for the development of pharmacotherapies to MDMA dependence.

Behavioural Pharmacology April 2016 Concepción Roger-Sánchez, María P García-Pardo, Marta Rodríguez‐arias et al.

In recent years, studies with animal models of reward, such as the intracranial self-stimulation, self-administration, and conditioned place preference paradigms, have increased our knowledge on the neurochemical substrates of the rewarding effects of 3,4-methylenedioxymetamphetamine (MDMA) in rodents. However, pharmacological and neuroimaging studies with human participants are scarce....

Potentiation of Ecstasy-induced hyperthermia and FAT/CD36 expression in chronically exercised animals.

Temperature March 30, 2016 Sandra L Hrometz, Jeremy A Ebert, Karen E Grice et al.

Fatal hyperthermia as a result of 3,4-methylenedioxymethamphetamine (MDMA) use involves non-esterified free fatty acids (NEFA) and the activation of mitochondrial uncoupling proteins (UCP). NEFA gain access into skeletal muscle via specific transport proteins, including fatty acid translocase (FAT/CD36). FAT/CD36 expression is known to increase following chronic exercise. Previous studies have...

The History of MDMA as an Underground Drug in the United States, 1960–1979

Journal of Psychoactive Drugs March 3, 2016 Torsten Passie, Udo Benzenhöfer 56 citations

MDMA (3,4-methylenedioxy-methylamphetamine, a.k.a. "ecstasy") was first synthesized in 1912 and resynthesized more than once for pharmaceutical reasons before it became a popular recreational drug. Partially based on previously overlooked U.S. government documentation, this article reconstructs the early history of MDMA as a recreational drug in the U.S. from 1960 to 1979. According to the...

3,4‐methylenedioxymethamphetamine increases excitability in the dentate gyrus: role of 5HT2A receptor‐inducedPGE2 signaling

Journal of Neurochemistry March 1, 2016 Stuart A. Collins, Courtney L Huff, Nicolas Chiaia et al.

Abstract: 3,4‐methylenedioxymethamphetamine (MDMA) is a widely abused psychostimulant, which causes release of serotonin in various forebrain regions. Recently, we reported thatMDMAincreases extracellular glutamate concentrations in the dentate gyrus, via activation of 5HT2A receptors. We examined the role of prostaglandin signaling in mediating the effects of 5HT2A receptor activation on the...

Prevention of drug priming- and cue-induced reinstatement of MDMA-seeking behaviors by the CB1 cannabinoid receptor antagonist AM251.

Drug and Alcohol Dependence March 1, 2016 Yoko Nawata, Kiyoyuki Kitaichi, Tsuneyuki Yamamoto

3,4-Methylenedioxymethamphetamine (MDMA), a methamphetamine (METH) derivative, exhibits METH-like actions at monoamine transporters and positive reinforcing effects in rodents and primates. The purposes of the present study were to determine whether cross-reinstatement would be observed between MDMA and METH and if the cannabinoid receptor, a receptor known to play critical roles in the brain...

DOI: 10.1016/j.drugalcdep.2015.12.016 (opens in new tab) Full text (opens in new tab) MDMA Cb1 cannabinoid receptor Drug-seeking behavior Methamphetamine +1

Can ecstasy treat the agony of PTSD?

European Psychiatry March 1, 2016 M. Mithoefer

IntroductionTwo serotonin reuptake inhibitors (SSRIs) have received FDA indication for treatment of PTSD, however the effectiveness of pharmacotherapy for PTSD is limited. Psychotherapy, including several well established evidence based methods, is the mainstay of PTSD treatment. Despite advances in this area, a significant percentage of PTSD patients are refractory to existing treatments....

DOI: 10.1016/j.eurpsy.2016.01.798 (opens in new tab) PTSD Treatment MDMA-Assisted Therapy Mental health improvement Clinical research

Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective

PLoS One February 23, 2016 Kim P. C. Kuypers, Eef L. Theunissen, Janelle H. P. van Wel et al. 23 citations

BACKGROUND: Ecstasy use has been associated with short-term and long-term memory deficits on a standard Word Learning Task (WLT). The clinical relevance of this has been debated and is currently unknown. The present study aimed at evaluating the clinical relevance of verbal memory impairment in Ecstasy users. To that end, clinical memory impairment was defined as decrement in memory performance...

Religion and Ecstasy in Seventeenth Century Italy

Inquiry@Queen's Undergraduate Research Conference Proceedings February 5, 2016 Emilija Babich

In the seventeenth century, the supremacy of the Catholic Church was being threatened both by science and by the growth of Protestantism. Rome, as the only remaining centre for Catholicism, needed to reassert its authority and reclaim those who had lost their faith. As a result, religious artistic production of the seventeenth century took on a spectacular and theatrical character that sought...

Constructing the ecstasy of MDMA from its component mental organs: Proposing the primer/probe method.

Medical Hypotheses February 1, 2016 Thomas S. Ray 6 citations

The drug MDMA, commonly known as ecstasy, produces a specific and distinct open hearted mental state, which led to the creation of a new pharmacological class, "entactogens". Extensive literature on its mechanisms of action has come to characterize MDMA as a "messy" drug with multiple mechanisms, but the consensus is that the distinctive entactogenic effects arise from the release of...

DOI: 10.1016/j.mehy.2015.12.018 (opens in new tab) Full text (opens in new tab) Mental organs Neuron groups Specific mental states Complex brain states +10

Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine.

Toxicology Letters January 22, 2016 Andrea E. Steuer, Martina I. Boxler, Lorena Stock et al.

Neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA) is still controversially discussed. Formation of reactive oxygen species e.g. based on elevated dopamine (DA) concentrations and DA quinone formation is discussed among others. Inhibition potential of MDMA metabolites regarding neurotransmitter degradation by catechol-O-methyltransferase and sulfotransferase was described previously....